GTC Biotherapeutics (fka GTCB)

[stockdak]

I think this answers one of Pre_Clinicals questions doesn't it?

The patent states that the goat production system produces Mabs that are deficient in fucose. These Mabs show a better ADCC response.

In this case the different glycosylation in the goat system is an advantage. This may not always be the case.

I am not as concerned as Pre-Clinical about the decreased half-life of Atryn. I believe it is given by continuous infusion during surgery and the goats make kgs of the material so being limited by amount of the protein is not a real issue.

Again one can speculate all you want about if goat produced proteins will be better or worse for a given application. The proof is in the clinical trials and not before.

In the view of the EMEA the company has shown that Atryn works so enough said in that regard IMO.

DAK